SYNPO2 Antibody
| Code | Size | Price |
|---|
| PSI-6051-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6051-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
SYNPO2 Antibody: Synaptopodin-2, Genethonin-2
Application Note:
SYNPO2 antibody can be used for detection of SYNPO2 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
SYNPO2 Antibody: SYNPO2 was initially identified as myopodin, a member of the synaptopodin family that contains one PPXY motif and multiple PXXP motifs. It colocalizes with alpha-actinin and is found at the Z-disc and during stress conditions will translocate to the nucleus, suggesting that it is part of signaling pathways in addition to its function as a structural protein. SYNPO2 has been shown to bind to calmodulin, alpha-actinin, and smooth muscle myosin and will stimulate actin polymerization in a calmodulin dependent manner, consistent with its proposed role in organizing the cytoskeleton. While deletion of SYNPO2 has been reported to be highly correlated with the invasiveness of prostate cancers, other reports suggest that down-regulation of SYNPO2 reduces the invasiveness and motility of prostate cancer cells.
Background References:
- Weins A, Schwarz K, Faul C, et al. Differentiation- and stress-dependent nuclear cytoplasmic redistribution of myopodin, a novel actin-bundling protein. J. Cell Biol.2001; 155:393-404.
- Shroeter MM, Beall B, Heid HW, et al. In vitro characterization of native mammalian smooth-muscle protein synaptopodin. Biosci. Rep.2008; 195-203.
- Lin F, Yu YP, Woods J, et al. Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. Am. J. Path.2001; 5:1603-12.
- De Ganck A, De Corte V, Bruyneel E, et al. Down-regulation of myopodin expression reduces invasion and motility of PC-3 prostate cancer cells. Int. J. Oncol.2009; 34:1403-9.
Buffer:
SYNPO2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
SYNPO2 antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human SYNPO2.
The immunogen is located within amino acids 320 - 370 of SYNPO2.
The immunogen is located within amino acids 320 - 370 of SYNPO2.
NCBI Gene ID #:
171024
NCBI Official Name:
synaptopodin 2
NCBI Official Symbol:
SYNPO2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_597734
Protein GI Number:
193083183
Purification:
SYNPO2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
Swissprot #:
Q9UMS6
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SYNPO2 Peptide | PSI-6051P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|